Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of BIVV020 in CIDP
2020-004006-54Phase 2Active
- Sponsor
- Sanofi
- Start
- Dec 2020
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of riliprubart in chronic inflammatory demyelinating polyneuropathy (CIDP) (3 arms), sponsored by Sanofi. Primary endpoint: Part A SOC-treated primary efficacy endpoint. Started Dec 2020; status: active.
02
Drugs
riliprubart
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on 2020-004006-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004006-54.